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Abstract 
 
 Ursolic acid has been widely known to possess biological activity against numerous 
tumor cell lines. Previous studies revealed its cytotoxicity on several cancer cells in vitro by 
either inducing apoptosis or cell cycle modulation. This study was conducted to investigate 
ursolic acid’s cytotoxicity solely and in combination with a chemotherapeutic agent, 
doxorubicin, on MCF-7 breast cancer cells, followed by observation on its mechanism. 
Cytotoxicity of single and combinational treatment of ursolic acid and doxorubicin on MCF-7 
breast cancer cells were conducted by using MTT assay. Single treatment was then evaluated 
by determining IC50 value, while combinational treatment was evaluated by analyzing cell 
viability and evaluating combination index (CI). To explore the mechanism underlying 
cytotoxic effect on respected cells, further analysis on cell cycle profile of single and 
combinational treatment was conducted by flow cytometry. Twenty four hours treatment of 
ursolic acid inhibited MCF-7 cells’ growth with IC50 value of 37 µM, while combinational 
treatment showed that several concentration combinations of ursolic acid and doxorubicin 
exhibited synergism of cytotoxic activity on MCF-7 cells, giving optimum CI value of 0.54. 
Flow cytometric analysis showed that combinational treatment induced G2/M arrest in MCF-
7 cells. These results show that ursolic acid is promising to be developed as either single 
chemopreventive agent, or as doxorubicin’s co-chemotherapeutic agent in breast cancer 
treatment. Observation on the selectivity as part of safety aspect together with in silico, in 
vitro, and in vivo study on its molecular mechanism should be conducted. 
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INTRODUCTION 
 
Ursolic acid, a pentacyclic triterpenoid 
found in plants, has been widely known to 
possess numerous biological activities, one of 
which is its activity against tumor cell lines. 
Previous researches observed that ursolic acid 
was able to inhibit SK-OV-3 and A2780 
ovarian cancer cells growth by inducing 
apoptosis (Song et al., 2012) and HepG2 cells 
proliferation by inducing apoptosis and through 
cell cycle modulation (Tian et al., 2006). 
Another research reported that MCF-7 breast 
cancer cells proliferation was inhibited by 
ursolic acid through cell cycle modulation, 
indicating its possible potential as a medical 
component for breast neoplasm (Zhang et al., 
2005). 
Breast cancer has been widely known to 
be the cancer suffered most among women. To 
date, chemotherapy using cytotoxic 
chemotherapeutic agents are still the major 
choice of treatment in cancer, especially 
metastatic cancer (Drummond, 2007). 
Doxorubicin is one of cancer chemotherapeutic 
agent widely used in breast cancer treatment 
(Childs et al., 2002). Doxorubicin’s cytotoxic 
effect occurs via p53 pathway. One of the major 
problems faced in doxorubicin therapy is the 
occurrence of resistance (Mechetner et al., 
1998).  
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Cancer’s resistance to doxorubicin occurs 
through various mechanisms, example drug 
inactivation, drug-pumping-out by efflux 
pumps on cell membrane, mutation of the 
target, and failure of apoptosis initiation (Davis 
et al., 2003; Notarbartolo et al., 2005). To 
overcome cancer’s resistance towards existing 
chemotherapy agent, the application of co-
chemotherapeutic agent in cancer therapy could 
be done. 
Previous research reported that ursolic 
acid inhibited MCF-7 cells growth by inducing 
apoptosis (Zhang et al., 2005). In this study, we 
observed ursolic acid’s ability in increasing 
doxorubicin cytotoxicity on breast cancer cells, 
allowing the use of lower dose of the 
chemotherapeutic agent giving less toxicity on 
normal tissues. The study of its molecular 
mechanism is also necessary. This study aimed 
to examine the cytotoxicity of ursolic acid on 
MCF-7 breast cancer cells, continued with its 
effect in combination with doxorubicin. 
 
MATERIALS AND METHODS 
 
Materials 
Ursolic acid (Sigma) was dissolved in 
Dimethyl Sulfoxide (DMSO) (Sigma). Both 5 
mg/ml doxorubicin (Ebewe) and ursolic acid 
solution were then diluted in DMEM cell 
culture medium before being applied. DMSO 
was used as the co-solvent in dissolving ursolic 
acid in DMEM culture medium. 
For cytotoxicity assay, 10% sodium 
dodecyl sulphate (SDS) (Merck) dissolved in 
0.01 N HCl (Merck) as stopper reagent, 
phosphate buffer saline (PBS) pH 7.4 
containing KCl (HPLC grade, Sigma), NaCl 
(HPLC grade, Sigma), Na2HPO4 (HPLC grade), 
and KH2PO4 (HPLC grade, Sigma) dissolved in 
aquadest as washing reagent, and 3-[4,5-
dimethyl thiazole-2-yl(-2,5- 
diphenyltetrazoliumbromide)] (MTT) dissolved 
in PBS as MTT reagent were used. 
For cell cycle analysis using 
flowcytometry, Phosphate Buffer Saline (PBS) 
pH 7.4, Propidium Iodide Solution (50 µg/ml in 
PBS containing 1% Triton X-100) and RNAse 
DNAse-free (20 µg/ml) reagents were used. 
 
MCF-7 Cells Culture  
MCF-7 cells were obtained from the 
collection of Cancer Chemoprevention 
Research Center (CCRC), Universitas Gadjah 
Mada. The cell line was a gift from Prof. 
Masashi Kawaichi, Nara Institute of Science 
and Technology (NAIST), Japan. 
 
Instruments 
Treated tissue culture dish ᴓ 10 cm 
(Iwaki), 96-well plate (Iwaki), 6-well plate 
(Iwaki), glassware, LAF hood (Labconco), CO2 
incubator (Heraeus), inverted microscope (Zeiss 
MC80), cell counter, water bath, analytical 
balance (Sartorius), micropipette (Gilson), 
optical microscope, centrifuge (Sorvall), ELISA 
reader (SLT 240 ATC), yellow tip, blue tip, 
haemocytometer, conical tube (Nunc), shaker 
(MRK-RETAC), vortex, sterile eppendorf 
(Plasti Brand), digital camera (Canon, Japan), 
FACS Calibur (BD). 
 
Cytotoxicity and Combinational Assay 
MCF-7 cells were cultured in DMEM 
(Gibco) Culture Medium containing 10%
v
/v 
Fetal Bovine Serum (FBS) (Gibco) and 1% 
Penicillin-Streptomycin (Gibco). Trypsin-
EDTA 0.25% (Gibco) was used in to de-
attached cells from TCD. The effect of ursolic 
acid alone and in combination with doxorubicin 
treatment on MCF-7 cells were measured based 
on MTT assay. MCF-7 cells were distributed to 
96-well plate with the density of 5 x 10
3
 
cells/well and incubated in 37˚C with 5% CO2 
for 24 hours. After 24 hours exposure of sample 
treatment, MTT reagent was applied, followed 
by 4 hours incubation. Stopper reagent was then 
applied. Plate was then kept with protection 
from light overnight, continued with 
absorbance determination (λ 595 nm) using 
ELISA reader (Bio-Rad). 
 
Flow Cytometric Analysis 
MCF-7 cells were distributed in to 6-well 
plate with the density of 10
6
 cells/well. After 24 
hours incubation, cells were treated with ursolic 
acid alone and in combination with 
doxorubicin. Following 24 hours treatment, 
cells were trypsinized and centrifuged at 2000 
rpm for 3 minutes. Collected cell pellets were 
then washed twice with cold PBS. Cells were 
resuspended in propidium iodide solution and 
treated with RNAse DNAse-free for 10 minutes 
at 37°C. Treated cells were then subjected to 
FACS flow cytometry. 
 
Data Analysis 
Single Cytotoxicity assay. Linear 
regression between ursolic acid concentration 
and % cell viability giving the equation y = Bx 
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+ A were used to calculate IC50 value, that is the 
concentration inhibiting 50% cell proliferation. 
Combinational Cytotoxicity Assay. Cell 
viability resulted in combinational treatment 
between each treatment were analyzed 
statistically by one-way ANOVA by using 
SPSS 17.0. Combinational treatment was also 
evaluated by calculating 
Combination Index (CI) value 
(Reynolds and Maurer, 2005), using the 
formula as follows. 
   
  
   
  
  
   
 
 
D1 and D2 represent concentrations used 
in combinational treatment, while Dx1 and Dx2 
are single treatment concentration giving the 
same response as D1 and D2, respectively. CI 
value acquired will allow the evaluation of 
ursolic acid’s potency in combinational 
treatment with doxorubicin on MCF-7 cells. 
Interpretation was done based on the 
classification listed in Table I. 
Flow Cytometry (Cell Cycle Profile). 
Cell cycle distribution was acquired by using 
ModFit LT 3.0 program. Analysis was done on 
the proportion of S-phase, G1-phase, and 
G2/M-phase expressed as percentage. 
 
 
Table I. Interpretation of CI value representing potency of combinational application 
CI value Interpretation CI Interpretation 
< 0.1 
0.1-0.3 
0.3-0.7 
0.7-0.9 
Very strongly synergist 
Strongly synergist 
Synergist 
Middle synergist 
0.9-1.1 
1.1-1.45 
1.45-3.3 
> 3.3 
Closely additive 
Middle antagonist 
Antagonist 
Strongly antagonist 
 
 
RESULTS AND DISCUSSION 
 
This study was conducted to explore 
ursolic acid’s potency as doxorubicin’s co-
chemotherapeutic agent against breast cancer, 
since MCF-7 breast cancer cells have been 
known to possess low sensitivity against 
doxorubicin (Zampieri et al., 2002).  
 
Ursolic Acid Inhibited MCF-7 Cells’ 
Growth 
Single cytotoxicity assay was conducted 
to evaluate ursolic acid’s cytotoxicity towards 
MCF-7 cells. Linear regression of ursolic acid 
concentration against % cell viability (Fig. 1) 
gave value of 37 µM. Treatment of ursolic acid 
on MCF-7 cells showed cell growth inhibition 
in a concentration-dependent manner. 
Therefore, ursolic acid exhibited potent 
cytotoxic activity on MCF-7 cells according to 
Teng et al. (2005). Ursolic acid possesses 
higher cytotoxicity to MCF-7 cells compared to 
naringenin (IC50 520 µM), a flavonoid found in 
the genus citrus (Fitriasari et al., 2010). 
However, compared to solamargine (IC50 2.1 
µM), a glycoalkaloid occurs in solanum species 
(Wei et al., 2011), ursolic acid possess 
relatively lower cytotoxicity on MCF-7 cells. 
According to Meiyanto et al. (2012), despite of 
Citrus flavonoids’ low cytotoxicity, they 
worked synergistically with doxorubicin to 
inhibit MCF-7 cells growth, revealing their 
potency as co-chemotherapeutic agents. We 
further observe ursolic acid’s ability to enhance 
doxorubicin’s cytotoxic effect on MCF-7 cells. 
Combinational assay was then conducted to 
observe whether ursolic acid would work 
synergistically with doxorubicin, a 
chemotherapeutic agent commonly used in 
breast cancer therapy, on MCF-7 breast cancer 
cells. 
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Figure 1. Ursolic acid decreased MCF-7 cells’ viability. Cell viability resulted from 24-hours treatment 
of ursolic acid on MCF-7 cells acquired by MTT assay. Five thousand cells per well were 
incubated and exposed with a series concentration of ursolic acid for 24 hours each. MTT 
reagent was then applied, followed by addition of stopper reagent and overnight 
incubation. Absorbance was determined at λ 595 nm using ELISA reader. Ursolic acid 
inhibited cell growth in a dose-dependent manner, giving IC50 value of 37 µM. Ursolic acid’s 
cytotoxicity was represented as percentage of MCF-7 cells’ viability as the mean + SE of 
three values. 
 
Ursolic Acid Increased Doxorubicin’s 
Cytotoxicity on MCF-7 Cells 
Combinational treatment of doxorubicin 
and ursolic acid on MCF-7 cells was conducted 
to observe the ability of ursolic acid to increase 
doxorubicin’s cytotoxicity on MCF-7 cells. We 
set the experimental design of combinational 
treatment based on single compound 
cytotoxicity, represented by IC50 values. 
Doxorubicin’s IC50 value on MCF-7 cells was 
350 nM (CCRC, unpublished data). 
Combinational treatment of ursolic acid and 
doxorubicin on MCF-7 cells resulted in higher 
cell growth inhibition compared to single 
treatment (p<0.05) (Table II, Fig. 2). Several 
concentration combinations showed synergism 
on MCF-7 cells, with CI values less than 0.9 
(Table III). Cell morphology after treatment 
was also observed (Fig. 3). Treatment of ursolic 
acid and doxorubicin alone led to cells’ 
morphological changes, (Fig. 3(B) and 3(C)). 
Combination of them caused more changes 
compared to single treated cells, and less viable 
cells (Fig. 3(D)), while control cells showed 
only slight changes in cells’ morphology (Fig. 
3(A)). Flow cytometric analysis was then 
conducted to observe cell cycle modulation of 
combination of ursolic acid and doxorubicin on 
MCF-7 cells. 
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Figure 2. Combination of ursolic acid and doxorubicin inhibited T47D cells growth. Twenty four-
hours treatment of ursolic acid (UA) and doxorubicin (Dox) on MCF-7 cells examined by 
MTT assay. Five thousand cells per well were incubated for 24 hours and were exposed with 
various concentrations of ursolic acid and doxorubicin solely and in combination. MTT 
reagent was then applied, followed by addition of stopper reagent and overnight incubation. 
Absorbance was determined at λ 595 nm using ELISA reader. One-way ANOVA statistical 
analysis was conducted to determine significant difference of cell viability yielded between 
treatments. Note (*) shows significant difference of combinational treatment compared to 
single treatments (p 0.05). Combinational treatment of ursolic acid and doxorubicin yielded 
less cell viability compared to single treatment. Cytotoxicity was represented as percentage 
of MCF-7 cells’ viability as the mean + SE of three values. 
 
 
 
  (A) 
 
(B) 
 
(C) 
 
(D) 
Figure 3. Combination of doxorubicin and ursolic acid showed synergism. Twenty four-hours 
treatment of ursolic acid and doxorubicin on MCF-7 cells. Cells were exposed with samples 
for 24 hours, followed by observation of 24-hours treatment of (A) vehicle only; (B) 1/4 IC50 
doxorubicin; (C) 2/5 IC50 ursolic acid; (D) 1/4 IC50 doxorubicin in combination with 2/5 IC50 
ursolic acid. Change in cell morphology is pointed with black arrows. Observation was done 
by using inverted microscope, 100x magnification. 
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Table II. Effect of single and combinational treatment of ursolic acid and doxorubicin on MCF-7 cells 
viability. 
MCF-7 Cells Viability (% viability + SE) 
Ursolic acid 
concentration (IC50) 
IC50 = 37 μM 
Doxorubicin (IC50) 
IC50 = 350 nM 
0 1/10 1/4 1/3 1/2 
0 - 124.20 + 4.11* 115.37 + 1.95* 93.54 + 1.56* 73.61 + 1.57* 
2/5 91.50 + 1.87 87.49 + 3.68* 61.00 + 2.68* 46.61 + 1.14* 40.23 + 2.63* 
1/2 69.01 + 1.47 63.45 + 2.34* 28.95 + 2.66* 28.78 + 1.61* 23.39 + 2.06* 
7/9 53.64 + 3.13* 40.31 + 2.44* 13.49 + 2.05* 13.49 + 1.02* 10.87 + 0.43* 
* sign shows significant difference of cell viability resulted in combinational treatments compared to those yielded 
by both single treatments. 
 
 
Table III. Combination Index of combinational treatment of ursolic acid and doxorubicin on MCF-7 
cells. 
Combination Index 
Ursolic acid concentration (IC50) 
Doxorubicin (IC50) 
1/10 1/4 1/3 1/2 
2/5 2.65 3.26 0.69 0.59 
1/2 1.47 1.02 0.60 0.54 
7/9 1.17 0.60 0.65 0.63 
* Bold numbers shows combination resulting in CI value below 0.9, which are synergist. 
 
Ursolic Acid Solely and in Combination 
with Doxorubicin Altered Cell Cycle 
Profile of MCF-7 Cells 
In this research, treatment of ursolic acid 
alone led to S phase arrest, while doxorubicin 
induced accumulation in G2/M phase (Fig. 4). 
Combinational treatment of both compounds 
tends to increase cell population in G2/M phase 
(Fig. 4). G2/M arrest showed occurrence of 
disruption in cell growth process that may lead 
to apoptosis. 
 
Possible Underlying Mechanism and 
Proposed Future Studies 
Combinational treatment of ursolic acid 
and doxorubicin was conducted to explore 
ursolic acid’s potency to be developed as co-
chemotherapeutic agent. The use of co-
chemotherapeutic agent having synergistic 
effect may allow the use of lower dosage of 
chemotherapeutic agent, resulting in the 
decrease of cytotoxicity on normal cells (Bastl 
et al., 2007). Combinational treatment of 
ursolic acid and doxorubicin on MCF-7 cells 
resulted in higher cell growth inhibition 
compared to single treatment exhibited 
synergism in several combinations of 
concentration. Cell growth inhibition may occur 
via either apoptosis induction or cell cycle 
modulation or both occurring consecutively. 
Zhang et al. (2005) and Kassi et al. (2009) 
reported that ursolic acid inhibited MCF-7 cells 
growth by downregulating Bcl-2 that leads to 
apoptosis induction. Our study by flow 
cytometric analysis showed that ursolic acid 
alone led to S phase arrest, while in 
combinational treatment it tend to cause G2/M  
arrest. Both S and G2/M arrest showed 
disruption in cell growth process, which could 
be in either DNA synthesis or cytokinesis. That 
phenomenon may lead to apoptosis. 
Another study revealed that ursolic 
acid-induced apoptosis was followed by a 
decrease in CDK4/cyclin D1 expression 
through suppression of FoxM1 expression 
(Wang et al., 2012). CDK4/cyclin D complex 
plays a role in G1 phase activation (Shah and 
Schwartz, 2006). Inhibition of G1 activation 
may lead to disruption of protein synthesis (S 
phase), that may responsible for the S phase 
arrest. A study revealing ursolic acid’s effect to 
CDK2/cyclin, a complex that is responsible for 
the activation of S phase is suggested (Hsu et 
al., 2004). It has also been observed that ursolic 
acid increased p53 expression (Zhang et al., 
2005). p53 protein will be expressed and 
activated due to DNA damage. The p53 will 
then induce the expression of cyclin dependent 
kinase inhibitors (CKIs), such as p21, p27, and 
p57 that play a role in inhibiting CDK/cyclin 
complex activity, resulting in the disruption of 
cell cycle (Foster, 2008). The effect of ursolic 
Arifin, et al., 2012 
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acid in combination with doxorubicin on 
proteins involved in G2/M activation in MCF-7 
cells, such as MPF, are also proposed to be 
further studied, to understand the mechanism of 
ursolic acid’s ability to increase doxorubicin’s 
cytotoxicity on MCF-7 cells. One protein 
playing a role in cell growth and apoptosis is 
NF-κB, commonly found as heterodimer 
(Moynagh, 2005). Observation on the effect of 
ursolic acid treatment solely and in combination 
with doxorubicin to NF-κB activation in MCF-
7 cells is also suggested. Besides, study on its 
selectivity of cytotoxicity is also needed. 
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Figure 4. Ursolic acid solely and in combination with doxorubicin modulates cell cycle of MCF-7 cells. 
One million cells/well were incubated, followed by exprosure of samples for 24 hours. Cells 
were then trypsinized and collected. Following addition on 50 μg/ml propidium iodide 
solution and 20 μg/ml RNAse DNAse-free, cells were subjected to FACS flow cytometer. 
Data acquired were analyzed by using ModFit LT 3.0 program. Flow cytometric analysis of 
(A) vehicle-treated cells; 24-hours treatment of (B)1/10 IC50 ursolic acid; (C) 1/4 IC50 ursolic 
acid; (D) 1/2 IC50 doxorubicin; (E) 1/2 IC50 doxorubicin in combination with 1/10 IC50 ursolic 
acid; (F) 1/2 IC50 doxorubicin in combination with 1/4 IC50 ursolic acid on MCF-7 cells. 
 
 
According to the data above, we 
conclude that ursolic acid is promising to be 
developed as single chemopreventive agent, 
and also as doxorubicin’s co-chemotherapeutic 
agent in breast cancer treatment. Observation 
on its selectivity as part of safety aspect is also 
needed. Further in silico, in vitro, and in vivo 
study on its molecular mechanism also should 
be conducted. 
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